Patients with IBD who were exposed to anti-TNF therapy had a significant decrease in incidence of PD
WEDNESDAY, April 25, 2018 (HealthDay News) — Patients with inflammatory bowel disease (IBD) have increased incidence of Parkinson’s disease (PD), which is attenuated with anti-tumor necrosis factor (TNF) therapy, according to a study published online April 23 in JAMA Neurology.
Inga Peter, Ph.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues conducted a retrospective cohort study to compare the incidence of PD among individuals with or without IBD and to examine whether the risk of PD is affected by anti-TNF therapy. Data were analyzed from the Truven Health MarketScan administrative claims database and the Medicare Supplemental Database.
A total of 144,018 individuals with IBD and 720,090 age-, sex-, and year of index date-matched unaffected controls were included. The researchers found that 1,796 individuals had at least two PD diagnoses and at least one filled a PD-related prescription. Among patients with IBD, the incidence of PD was significantly higher than among unaffected matched controls (adjusted incidence rate ratio, 1.28). Patients with IBD who were exposed to anti-TNF therapy had a significant decrease in the incidence rate of PD compared with those not exposed (adjusted incidence rate ratio, 0.22).
“These findings support a role of systemic inflammation in the pathogenesis of both diseases. Further studies are required to determine whether anti-TNF treatment administered to high-risk individuals may mitigate PD risk,” the authors write.
Several authors disclosed financial ties to the pharmaceutical industry.
Copyright © 2018 HealthDay. All rights reserved.
